U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06880393) titled 'BCMA CAR-T for Dynamic High-risk Multiple Myeloma' on March 11.
Brief Summary: This is a single-arm, open-label study to evaluate the efficacy and safety of BCMA CAR-T in dynamic high-risk patients with multiple myeloma
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
BIOLOGICAL: anti-BCMA-CAR-T
Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10^6 anti-BCMA CAR+T cells/kg
Recruitment Status: RECRUITING
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Published by HT Digital Content Services with permission from He...